Printer Friendly

IsoPlexis expands single-cell systems with conclusion of USD 20m in Series C financing.

M2 EQUITYBITES-January 13, 2020-IsoPlexis expands single-cell systems with conclusion of USD 20m in Series C financing


IsoPlexis has announced that it has secured an additional USD 20 million to its Series C financing, bringing the entire Series C round to USD 45 million, the company said.

The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform. The recent financing was led by Northpond Ventures, along with participation from existing investors.

The IsoLight single-cell system is used globally by leading biotech, pharma and academic medical centers to solve critical challenges in cell therapy, cancer immunology, and inflammatory disease.

In 2020, IsoPlexis will continue to expand its applications and release innovative products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.

IsoPlexis is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its correlative single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, the company is advancing immunotherapies and targeted therapies to a more highly precise and personalized stage.

((Comments on this story may be sent to

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 13, 2020
Previous Article:Manulife Investment concludes private equity fund of USD 1.5bn.
Next Article:Osceola Capital acquires Florida's Healthcents.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters